Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Expands Indian Research Facility, Making it Company's Largest Worldwide

Premium

Agilent Technologies said this week that it has expanded its Life Sciences and Chemical Analysis Center of Excellence in Bangalore.

The center, which at 8,000 square feet is the company's largest research facility worldwide, now offers access to a number of its high-end products, including instruments like the 6490 triple-quadrupole and 6540 Q-TOF mass spectrometers and 1290 and 1260 Infinity LCs that are commonly used in proteomics research.

The company's core instruments are also on offer at the facility, including its range of liquid chromatographs and mass spectrometers. Customers can use the center to test the performance of Agilent products for their samples and applications.

In addition to the expansion of the center, Agilent has opened a life science application development lab, which it said in a statement is designed to "accelerate the discovery of life science analysis workflows."

"India continues to be one of the most important markets for Agilent globally, with a significant presence of high-end R&D in pharmaceuticals and biotechnology," country general manager for India, Parmeet Ahuja, said in a statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.